<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597438</url>
  </required_header>
  <id_info>
    <org_study_id>18-015056</org_study_id>
    <secondary_id>1R21NS103826-01</secondary_id>
    <nct_id>NCT03597438</nct_id>
  </id_info>
  <brief_title>National CounterACT Initiative</brief_title>
  <official_title>Mitochondrial Targeted Biofuels as Countermeasures Against Chemical Threats</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine in vitro effects on mitochondrial function of
      selected chemical agents in human cells, and assess the capability of a cell-permeable
      succinate prodrug to attenuate toxic effects The project aims at repurposing this recent
      pharmaceutical discovery, currently being developed for treatment of toxic exposure, for an
      expanded indication to treat chemically induced mitochondrial toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per subject will be approximately 15 minutes to complete the one time
      blood collection.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Attenuation by the succinate prodrug of toxin-induced decrease in mitochondrial respiration.</measure>
    <time_frame>by end of 2018</time_frame>
    <description>Data will be assessed using 2-tailed Student's t-test. Dose-response curves for respiration will be made for each toxin and IC50 calculated. In case of difficulties in demonstrating acute toxicity of chemical agents, dose-titration experiments and long-term incubation (up to 24 hours) will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attenuation of toxin-induced decrease in mitochondrial membrane potential and attenuate lactate production by the succinate prodrug.</measure>
    <time_frame>by end of 2018</time_frame>
    <description>Data will be assessed using 2-tailed Student's t-test. Dose-response curves for respiration will be made for each toxin and IC50 calculated. In case of difficulties in demonstrating acute toxicity of chemical agents, dose-titration experiments and long-term incubation (up to 24 h) will be performed</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Mitochondrial Alteration</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volunteer</arm_group_label>
    <description>Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for elective surgery will be screened for eligibility. Volunteers who
        are employees, trainees, and students will be screened for eligibility.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:

          1. Males or females age greater or equal 2 years of age

          2. Weight greater or equal to 10 kg

          3. Parental/guardian permission (informed consent) and if appropriate, child assent.

        Patient Exclusion Criteria:

          1. Known primary mitochondrial disorder.

          2. Use of an investigational drug within 30 days prior to enrollment.

          3. Parents/guardians or subjects who in the opinion of the Investigator, may be
             non-compliant with study schedules or procedures.

        Volunteer Inclusion Criteria

          1. Males or females &gt; 18 years of age

          2. Employee, trainee, or student informed consent

        Volunteer Exclusion Criteria:

          1. Prior enrollment in this study.

          2. Known primary mitochondrial disorder.

          3. Use of an investigational drug within 30 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd J Kilbaugh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jeevaratnam K, Vidya S, Vaidyanathan CS. In vitro and in vivo effect of methyl isocyanate on rat liver mitochondrial respiration. Toxicol Appl Pharmacol. 1992 Dec;117(2):172-9.</citation>
    <PMID>1471148</PMID>
  </reference>
  <reference>
    <citation>Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E. Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency. Nat Commun. 2016 Aug 9;7:12317. doi: 10.1038/ncomms12317.</citation>
    <PMID>27502960</PMID>
  </reference>
  <reference>
    <citation>Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1998 May 6;1364(2):222-35. Review.</citation>
    <PMID>9593904</PMID>
  </reference>
  <reference>
    <citation>Mesnage R, Arno M, Costanzo M, Malatesta M, Séralini GE, Antoniou MN. Transcriptome profile analysis reflects rat liver and kidney damage following chronic ultra-low dose Roundup exposure. Environ Health. 2015 Aug 25;14:70. doi: 10.1186/s12940-015-0056-1. Erratum in: Environ Health. 2017 Mar 23;16(1):28.</citation>
    <PMID>26302742</PMID>
  </reference>
  <reference>
    <citation>Friedrich T, van Heek P, Leif H, Ohnishi T, Forche E, Kunze B, Jansen R, Trowitzsch-Kienast W, Höfle G, Reichenbach H, et al. Two binding sites of inhibitors in NADH: ubiquinone oxidoreductase (complex I). Relationship of one site with the ubiquinone-binding site of bacterial glucose:ubiquinone oxidoreductase. Eur J Biochem. 1994 Jan 15;219(1-2):691-8.</citation>
    <PMID>8307034</PMID>
  </reference>
  <reference>
    <citation>Lim S, Ahn SY, Song IC, Chung MH, Jang HC, Park KS, Lee KU, Pak YK, Lee HK. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One. 2009;4(4):e5186. doi: 10.1371/journal.pone.0005186. Epub 2009 Apr 13.</citation>
    <PMID>19365547</PMID>
  </reference>
  <reference>
    <citation>Hase Y, Tatsuno M, Nishi T, Kataoka K, Kabe Y, Yamaguchi Y, Ozawa N, Natori M, Handa H, Watanabe H. Atrazine binds to F1F0-ATP synthase and inhibits mitochondrial function in sperm. Biochem Biophys Res Commun. 2008 Feb 1;366(1):66-72. Epub 2007 Dec 4.</citation>
    <PMID>18060860</PMID>
  </reference>
  <reference>
    <citation>Hollingworth RM, Ahammadsahib KI, Gadelhak G, McLaughlin JL. New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticides. Biochem Soc Trans. 1994 Feb;22(1):230-3. Review.</citation>
    <PMID>8206238</PMID>
  </reference>
  <reference>
    <citation>Satoh T, Miyoshi H, Sakamoto K, Iwamura H. Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases. Biochim Biophys Acta. 1996 Jan 11;1273(1):21-30.</citation>
    <PMID>8573592</PMID>
  </reference>
  <reference>
    <citation>Gassner B, Wüthrich A, Scholtysik G, Solioz M. The pyrethroids permethrin and cyhalothrin are potent inhibitors of the mitochondrial complex I. J Pharmacol Exp Ther. 1997 May;281(2):855-60.</citation>
    <PMID>9152394</PMID>
  </reference>
  <reference>
    <citation>Gunnell D, Eddleston M, Phillips MR, Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health. 2007 Dec 21;7:357. Review.</citation>
    <PMID>18154668</PMID>
  </reference>
  <reference>
    <citation>Bus JS, Gibson JE. Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect. 1984 Apr;55:37-46. Review.</citation>
    <PMID>6329674</PMID>
  </reference>
  <reference>
    <citation>Tawara T, Fukushima T, Hojo N, Isobe A, Shiwaku K, Setogawa T, Yamane Y. Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain. Arch Toxicol. 1996;70(9):585-9.</citation>
    <PMID>8831909</PMID>
  </reference>
  <reference>
    <citation>Eckerman I. THE BHOPAL SAGA: Universities Press (India); 2005.</citation>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

